by Vandana Singh | Oct 27, 2026 | General
Aclaris Therapeutics Inc. (NASDAQ:ACRS) reported positive primary analysis results from two Phase 1b proof-of-concept clinical trials evaluating its bispecific antibody ATI-052 in atopic dermatitis and asthma. Read Also: Aclaris Hair Loss Drug Shows Faster Results...
by Daragh Thomas | Oct 27, 2026 | General
Election forecaster Nate Silver says next week’s midterms could mark the “end of the Trump era,” as high gasoline prices and opposition to the Iran war add to President Donald Trump’s political troubles. “If the election goes roughly as the polls say it will go, then...
by Lekha Gupta | Oct 27, 2026 | General
Freeport-McMoRan (NYSE:FCX) stock traded higher Tuesday after the copper giant reported better-than-expected third-quarter earnings.The company reported adjusted earnings of 88 cents per share, topping analysts’ consensus estimate of 79 cents. Revenue of $7.546...
by Vandana Singh | Oct 27, 2026 | General
Artiva Biotherapeutics Inc. (NASDAQ:ARTV) announced it will halt further clinical development of its lead cell therapy candidate, slash roughly 94% of its workforce, and evaluate strategic alternatives. The clinical-stage biotechnology company decided on its cell...
by Surbhi Jain | Oct 27, 2026 | General
Verizon Communications Inc. (NYSE:VZ) CEO Dan Schulman says Space Exploration Technologies Corp. (NASDAQ:SPCX) could face a bill of up to $500 billion if it wants to compete directly with U.S. wireless carriers. The estimate is not a SpaceX spending plan, but it...
Recent Comments